Sign in

CIK 0000748592 · Non-accelerated filer<br>Smaller reporting company

Ernexa Therapeutics Inc.

Sign in to watch
Ticker
ERNA
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
311103425
Phone
(617) 798-6700
Business address
1035 CAMBRIDGE STREET, SUITE 18A, CAMBRIDGE, MA, 02141
Former names
Eterna Therapeutics Inc., Brooklyn ImmunoTherapeutics, Inc., NTN BUZZTIME INC, NTN COMMUNICATIONS INC

Securities

  • ERNA Common Stock Nasdaq
  • ERNAW Warrants Nasdaq
  1. 8-K Event Executive or director change
  2. 4 Open-market buy CEO bought 150,000 shares at an average $0.34 ($50,992)
  3. 4 Open-market buy Director bought 510,000 shares at an average $0.34 ($173,500)
  4. SC 13D/A Stake Beneficial Ownership Report
  5. 10-Q Report Quarterly Report
  6. 8-K Event Results of operations
  7. 4 Open-market buy CEO bought 31,800 shares at an average $0.38 ($11,966)
  8. 4 Option exercise Director acquired 30,000 shares (option exercise)
  9. 4 Open-market buy CEO bought 20,000 shares at $0.41 ($8,200)
  10. 8-K Event Code of ethics change
  11. 10-Q Report Quarterly Report
  12. 8-K Event Results of operations · Regulation FD disclosure
  13. 3 Insider Initial Statement of Ownership
  14. 4 Derivatives Options or other derivatives
  15. 8-K Event Executive or director change
  16. 4 Open-market buy CEO bought 600 shares at $0.48 ($288)
  17. 4 Derivatives Options or other derivatives
  18. 3 Insider Initial Statement of Ownership
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. 4 Derivatives Options or other derivatives

Page 50 of 77 · 1,525 filings